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Background: To compare the short-term tumor response and long-term clinical outcome of two preoperative
chemoradiotherapy (CRT) regimens for locally advanced rectal cancer.
Methods: This study included 231 patients scheduled for preoperative CRT using two chemotherapeutic protocols
from April 2003–August 2006. Pelvic radiotherapy (50.4 Gy) was delivered concurrently with capecitabine (n = 148)
or capecitabine/irinotecan (n = 83). Surgery was performed 4–8 weeks after CRT completion. Tumor responses to CRT
were assessed using both radiologic and pathologic measurements. Radiologic responses were evaluated by magnetic
resonance volumetry, which was performed at the initial work-up and after completion of preoperative CRT just before
surgery. Pathologic responses were assessed with downstaging (ypStage 0-1) and grading tumor regression. Clinical
outcomes were evaluated in terms of local control, relapse-free survival, and overall survival rates.
Results: Radiologic examination demonstrated that tumor volume decreased by 65.6% in the capecitabine group
and 66.8% capecitabine/irinotecan group (p = 0.731). Postoperative pathologic stage determination showed that tumor
downstaging occurred in 44.1% of the capecitabine group and 48.6% of the capecitabine/irinotecan group (p = 0.538).
The sum of tumor regression grade 3 (near complete response) and 4 (complete response) after CRT were 28.6% in the
capecitabine group and 37.5% in the capecitabine/irinotecan group (p = 0.247). There were no significant differences
between the two groups in 5-year local control (91.7% vs. 92.5%; p = 0.875), relapse-free survival (80.8% vs. 77.2%;
p = 0.685), and overall survival (88.4% vs. 90.4%; p = 0.723).
Conclusions: This study revealed no differences in the short-term tumor response and long-term clinical outcome
between preoperative capecitabine and capecitabine/irinotecan CRT regimens for locally advanced rectal cancer.
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Locally advanced rectal cancer is currently treated with
a multidisciplinary approach since the combination of
surgery, chemotherapy and radiotherapy is necessary for
an optimal outcome. Preoperative chemoradiotherapy
(CRT) followed by radical surgery has become one of the
standard treatments for patients with locally advanced* Correspondence: radiopiakim@hanmail.net
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reproduction in any medium, provided the orrectal cancer and is superior to postoperative CRT by
reducing toxicity and improving the local control rate
[1]. The most commonly used chemotherapeutic agents
for CRT are fluoropyrimidines, including 5-fluorouracil
and capecitabine. Although preoperative CRT with 5-
fluorouracil has become part of standard therapy in
patients with locally advanced rectal cancer, the oral
fluoropyrimidine capecitabine has often be used in
place of 5-fluorouracil in CRT because of its convenience
and safety profile [2]. In addition, capecitabine is highly
selective toward tumor tissue because thymidine. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more abundantly expressed in tumors than in normal
tissue [3]. A recent multicenter phase III trial in
Germany confirmed that the endpoint overall survival
rates did not change when infused 5-fluorouracil was
replaced by the oral prodrug capecitabine during radio-
therapy and adjuvant chemotherapy [4].
Irinotecan, a topoisomerase I inhibitor, has shown effi-
cacy in combination with fluoropyrimidines in metastatic
colorectal cancer [5]. Several perioperative CRT trials have
demonstrated the feasibility of irinotecan and capecitabine
[6], and more recently, we reported the clinical outcomes
of the drugs in a phase II trial [7]. Although preoperative
CRT using the capecitabine/irinotecan regimen has proven
effective, those studies did not directly compare cape-
citabine alone and capecitabine/irinotecan as preopera-
tive CRT regimens for rectal cancer.
The aim of this study was to determine whether the
combination of irinotecan with capecitabine could be
more effective than capecitabine alone. Here, we report
our experience with capecitabine vs. capecitabine/irino-
tecan in evaluating the tumor response and survival after
preoperative CRT for locally advanced rectal cancer
when the chemotherapeutic agents were administered in
conjunction with preoperative radiotherapy.
Methods
Patients
The medical records of rectal adenocarcinoma patients
from April 2003–August 2006 were retrospectively
reviewed. Before April 2003, preoperative CRT with 5-
fluorouracil had been mainly used, however during this
period of time, the capecitabine started to be used as
preoperative CRT regimen and capecitabine/irinotecan
protocol was executed. This study included 231 patients
with primary rectal cancer who underwent preoperative
CRT under two chemotherapeutic regimens, either cape-
citabine or capecitabine/irinotecan. The inclusion criteria
were: (1) histologically proven adenocarcinoma (<9 cm
above the anal verge); (2) locally advanced disease
clinically staged as T3–4 and curatively resectable,
evaluated by pelvic magnetic resonance imaging with
or without transrectal ultrasonography; (3) no evidence of
distant metastasis in staging work-up.
Among the 231 patients, six refused surgery (only in
capecitabine group) and five patients in the capecitabine
group and eight patients in the capecitabine/irinotecan
group were treated with transanal local excision respect-
ively, because their co-morbidities made radical proctect-
omy impossible or they strongly disagreed with curative
surgery. In addition, three patients in capecitabine alone
group and one patient in the capecitabine/irinotecan
group moved to other hospitals to be closer to their
residence before surgery. The study was performed inaccordance with the guidelines of our institutional review
board, which deemed that informed consent was not
required because the study was a retrospective analysis.
Treatment
Preoperative chemotherapy
Preoperative chemotherapy was delivered concurrently
with pelvic radiation in 150 patients receiving capecita-
bine alone and 81 receiving capecitabine/irinotecan. The
capecitabine-only group was administered an oral 825 mg/
m2 dose twice daily with no drug holiday for the duration
of radiotherapy. The capecitabine/irinotecan group
received concurrent chemotherapy with 40 mg/m2 of
irinotecan per week for 5 consecutive weeks and oral
capecitabine at an 825 mg/m2 dose twice per day
(weekdays only) for the duration of radiotherapy. The
capecitabine protocol was executed between April
2003–April 2006, and capecitabine/irinotecan protocol
between August 2004–August 2006. In the overlap-
ping period, the protocol undertaken was determined
according to the preferences of patients or attending
physicians.
Radiotherapy
Preoperative radiotherapy of 45 Gy/25 fractions was
delivered to the whole pelvis, followed by 5.4 Gy/3
fractions boost to a restricted volume. All patients
underwent computed tomography (CT) simulation for
three-dimensional conformal radiotherapy, and had their
target volumes delineated according to the International
Commission on Radiation Units and Measurements
Report 50.
Surgery
Patients underwent open radical surgery 4–8 weeks
(median = 6 weeks) after completion of preoperative CRT.
Total mesorectal excision was the priority for surgical
treatment, with the final decision regarding the choice
of surgical procedure (low anterior or abdominoperineal
resection) being made by the surgeon after discussion
with the multidisciplinary team involved in the patient’s
treatment.
Postoperative chemotherapy
Regardless of pathologic stage, all patients underwent
postoperative chemotherapy, initiated within 3 or 4 weeks
after surgery. One of the following chemotherapeutic regi-
mens was used: four cycles of 5-fluorouracil/leucovorin;
six cycles of capecitabine; or six cycles of capecitabine and
oxaliplatin.
Evaluation
Short- and long-term endpoints were evaluated. The
short-term endpoint compared tumor response between
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the survival rates of the two groups.
Short-term tumor responses to CRT were assessed by:
(1) radiologic evaluation and (2) pathologic evaluation.
To evaluate the radiologic responses of the tumor, mag-
netic resonance volumetry was performed at the initial
workup and 2–4 days before surgery. Cross-sectional
areas of the lesions were measured by tracing the lesion
boundary on axial T2-weighted images. Based on mag-
netic resonance volumetry, the tumor volume reduction
rate was calculated using the equation R (%) = (VpreCRT –
VpostCRT) × 100/VpreCRT, where R represents the tumor
volume reduction rate, VpreCRT represents the pre-CRT
tumor volume, and VpostCRT represents the post-CRT
tumor volume. Clinical response was defined as a volume
reduction rate of ≥ 65% [8].
Pathologic responses of tumors were assessed by col-
lecting the following data for each surgical specimen:
histological adenocarcinoma grade, ypStage according to
the American Joint Committee on Cancer staging system
(6th edition) [9], and tumor regression grade. Downsta-
ging was determined by comparing the pretreatment
clinical and postoperative pathologic classifications and
defined as ypStage 0–I. Tumor regression grade was
classified using the scale proposed by Dworak et al [10].
We defined the overall tumor regression as Grade 3
(near complete response) and 4 (complete response) for
statistical analysis.
Patient follow-up
Patient follow-up was performed every 3 months for the
first 2 postoperative years and every 6 months thereafter.
Chest radiography and CT scanning of the abdomen and
pelvis were conducted every 6 months after surgery, and
video colonoscopy was performed at 1, 3, and 5 years
after surgery. The diagnosis of recurrence was confirmed
pathologically by surgical resection, biopsy or cytology,
and/or radiologic findings that increased in size over
time. Local recurrence was defined as any disease recur-
rence within the pelvis. Recurrence outside the pelvis
was classified as a distant metastasis.
Statistical analysis
This study was designed to retrospectively compare the
efficacy of two protocols by assessing tumor response
and survival rate. As mentioned above, radiologic and
the pathologic evaluations were used to evaluate tumor
response. The radiologic findings were analyzed to deter-
mine the mean volume reduction rate and clinical re-
sponse rate (volume reduction rate ≥ 65%). The pathologic
findings were used to determine downstaging and overall
tumor regression. The t-test and Fisher’s exact test were
used to compare various parameters between the two
chemotherapy groups. Relapse-free survival analysis wasbased on the time of disease recurrence, and overall sur-
vival analysis was based on the time of death from any
cause. Kaplan-Meier analysis was used to construct
relapse-free survival and overall survival curves. Differ-




The study population had a median age of 56 years
(range = 31–83 years) and was predominantly male (133
males, 75 females). The median distance from the anal
verge to the caudal edge of the tumor was 5 cm (range =
0–9 cm). The clinical staging work-up revealed cT3 in 201
patients (96.6%) and cT4 in seven patients (3.4%). The
patients’ characteristics were recorded according to the
two chemotherapeutic regimens and are presented in
Table 1. Statistical analysis revealed no significant differ-
ences between the capecitabine and capecitabine/irinote-
can groups in any category.
Radiologic findings
Magnetic resonance volumetry assessment was performed
for 216 patients (93.5%). The median pre-CRT tumor
volumes were 17.5 cm3 for capecitabine alone and
16.2 cm3 for capecitabine/irinotecan (p = 0.625). The me-
dian post-CRT tumor volume was 5.6 cm3 for capecitabine
alone and 5.2 cm3 for capecitabine/irinotecan (p = 0.681).
Of the 216 patients, 134 (62.0%) had clinical responses in
which the tumor volume was reduced ≥ 65%. The radio-
logic findings showed no differences between the capecita-
bine and capecitabine/irinotecan groups in terms of tumor
volume reduction rate and clinical response (Table 2).
Surgery
A total of 208 patients underwent curative surgery, al-
though 11 patients in the capecitabine group and seven in
the capecitabine/irinotecan group had a positive micro-
scopic circumferential resection margin. Distant metasta-
sis, which was not detected in the initial staging work-ups,
was discovered in the liver in only one patient in the cape-
citabine alone group during surgery. The sphincter was
preserved in 116 (85.2%) of 136 capecitabine alone
patients and 60 (83.3%) of 72 capecitabine/irinotecan
patients (p = 0.711). Of the 43 patients whose tumors were
located within 3 cm of the anal verge and were likely to
require sphincter ablation according to previous data [11],
the anal sphincter was preserved in 11 (40.7%) of 27 cape-
citabine alone patients and six (37.5%) of 16 capecitabine/
irinotecan patients (p = 0.838).
Pathologic findings
After radical surgery, pathologic assessment for 208
patients (100%) was undertaken. The pathologic staging
Table 1 Patients’ characteristics
Characteristic Capecitabine alone (n = 136) Capecitabine/Irinotecan (n = 72) p-value
Gender 0.991*
Male 87 (64.0) 46 (63.9)
Female 49 (36.0) 26 (36.1)
Age (years) 0.191†
Median, Range 57, 31-83 55, 32-74
Distance from anal verge (cm) 0.326†
Median, Range 5.5, 0-9.0 5, 0.5-9.0
cT classification 0.732*
cT3 131 (96.3) 70 (97.2)
cT4 5 (3.7) 2 (2.8)
Pre-CRT CEA (ng/ml) 0.319†
5 ≥ 87 (64.0) 51 (70.8)
5 < 49 (36.0) 21 (29.2)
CEA, carcinoembryonic antigen; CRT, chemoradiotherapy.
Data in parentheses are percentages.
*Two-tailed Fisher’s exact tests.
†Two-tailed t-test.
Lee et al. Radiation Oncology 2013, 8:258 Page 4 of 7
http://www.ro-journal.com/content/8/1/258of surgical specimens showed ypStage 0 in 37 patients
(17.8%), ypStage I in 58 patients (27.9%), ypStage II in
45 patients (21.6%), ypStage III in 67 patients (32.2%), and
ypStage IV in 1 (0.5%) patient. As a result of preoperative
CRT, downstaging to ypStage 0 or I occurred in 44.1% of
capecitabine patients and 48.6% of capecitabine/irinotecan
patients; no significant difference between two groups
was noted (p = 0.538).
Tumor regression in all patients was also evaluated.
According to Dworak’s regression grading scale, 32



















†Tumor volume reduction rate = (pre-CRT tumor volume – post-CRT tumor volume)
‡Two-tailed Fisher’s exact test.31 (14.9%) were Grade 3, and 36 (17.3%) were Grade 4.
Overall tumor regression (including regression at Grades
3 and 4) occurred in 29.4% of capecitabine patients and
37.5% of capecitabine/irinotecan patients and showed
no significant differences (p = 0.247; Table 2).Postoperative chemotherapy
Among the 208 patients who completed curative resection,
129 (94.9%) of 136 capecitabine-alone patients and 72
(100%) of 72 capecitabine/irinotecan patients (p = 0.098)tumor response
Capecitabine alone Capecitabine/Irinotecan p-value
137 79
0.731*
65.6 ± 24.3 66.8 ± 22.5
71.7 72.0
0–100 2.3–100
%) 82 (60) 52 (66) 0.384‡
131 70
0.538‡
60 (44.1) 35 (48.6)
76 (55.9) 37 (51.4)
0.247‡
96 (71.3) 45 (62.5)
40 (28.6) 27 (37.5)
× 100/pre-CRT tumor volume.
Lee et al. Radiation Oncology 2013, 8:258 Page 5 of 7
http://www.ro-journal.com/content/8/1/258started postoperative chemotherapy. Reasons for not
continuing with postoperative chemotherapy included
postoperative complications (n = 1), cytopenia (n = 2), pa-
tient refusal (n = 3) and poor performance status (n = 1).
The adjuvant chemotherapy regimen in the capecitabine-
alone group and capecitabine/irinotecan group was fluoro-
pyrimidine alone (91.9% vs. 94.4%) and in combination
with oxaliplatin (2.9% vs. 5.6%).Clinical outcomes
As of November, 2012, the median follow-up time was
77 months (range = 26–112 months). At this time point,
patients in the capecitabine alone group had 5-year local
control = 92.1%, relapse-free survival = 80.8%, and overall
survival rates = 88.5%. In the capecitabine/irinotecan
group, the patients had 5-year local control = 92.5%,
relapse-free survival = 76.0%, and overall survival rates =
91.7%. No statistically significant difference was found
in local control rate (p = 0.937), relapse-free survival
(p = 0.484), or overall survival rate (p = 0.598) between
the groups. Figure 1 shows the survival curve for each
group.Discussion
Fluorouracil-based chemoradiation is one of the most
widely chosen treatment options for preoperative treat-
ment of locally advanced rectal cancer. Substituting
fluorouracil with capecitabine, the fluorouracil prodrug,
is attractive because of the ease of administration and
mimicking of a continuous infusion [12]. A recent ran-
domized phase III trial in Germany confirmed that the
endpoint overall survival rates did not change when
infused 5-fluorouracil was replaced by capecitabine
during radiotherapy and adjuvant chemotherapy [4].
These findings mirror those of the large X-ACT trial
[13] of adjuvant capecitabine in colon cancer, which led
to FDA approval in 2005. The results of these two trials
seem to warrant replacement of fluorouracil with cape-
citabine for adjuvant therapy of rectal cancer. This has
caused increased interest in combining other chemo-
therapeutic agents, such as irinotecan, with capecita-
bine in order to enhance the effect of CRT.
Combining oxaliplatin or irinotecan with capecitabine is
the most frequently attempted regimen for heightening
CRT intensity because of the drug’s proven effectiveness
in colorectal cancer when combined with fluorouracil
[5,14]. Several randomized phase III trials adding oxali-
platin to capecitabine in preoperative CRT have been
completed to determine whether this combination shows
any advantage compared with the capecitabine alone.
Despite the expectation of a successful outcome, early
results from the NSABP R-04, ACCORD 12/0405-Prodige
2 trial did not confirm a significant improvement ofshort-term endpoints, such as the pathologic complete
response rate, by addition of oxaliplatin [15,16]. Results
of several preoperative CRT phase I/II studies using
capecitabine/irinotecan at various dosages and schedules
have been reported and showed encouraging tumor
response rates and toxicity profiles [6,17]. Willeke et al.
[17] reported a 15% pathologic complete remission rate
and 80% 3-year overall survival rate in their phase II
trial. In a capecitabine/irinotecan phase II study [7], we
reported well-tolerated toxicity profiles, with a notable
pathologic complete response rate (25.0%). We also re-
ported excellent clinical outcomes with a 3-year relapse-
free survival of 80.0% and overall survival rate of 94.7%.
In spite of excellent survival outcomes in our phase II
study, the data were interpreted cautiously due to the
relatively small number of patients (n = 48) [7]. In the
present study, 81 patients participated in the capecitabine/
irinotecan regimen, leading us to expect more reliable
statistical results. To assess the potential systemic benefit
of irinotecan addition, it was necessary to compare long-
term relapse-free survival associated with use of capecita-
bine/irinotecan with capecitabine alone. In the present
study, the capecitabine/irinotecan regimen failed to
improve relapse-free survival over capecitabine alone
(capecitabine alone vs. capecitabine/irinotecan; 81.4%
vs. 76.0%; p = 0.483). To our knowledge, this is the first
study to compare directly long-term survival and
short-term results in patients treated with capecita-
bine/irinotecan or capecitabine in preoperative CRT
for rectal cancer.
In this study, we used several methods to evaluate
tumor response before and after surgery. In doing so, we
compared not only the early results of two regimens, but
also correlated the early results with long-term clinical
outcome. We estimated the tumor volume reduction
rate to assess tumor response to CRT based on the
recent studies which reported that it was correlated well
with pathologic results and also could be a surrogate
indicator of patient prognosis [18,19]. The difference in
tumor volume reduction rates between the two groups
was non-significant (64.8% vs. 64.9%; p = 0.990). These
data therefore supported the hypothesis that the tumor
volume reduction rate correlates with pathologic response
and prognosis [18,19]. We also compared both regimens
to determine how each regimen yielded downstaging to
ypStage 0–I. Several previous studies reported that the es-
timation of downstaging to ypStage 0–I indicates a favor-
able prognostic patient group more than does assessment
of the pathologic complete response (ypStage 0) and could
be a reliable intermediate endpoint for preoperative CRT
in rectal cancer [20]. In this context, the downstaging that
occurred in each group was not significantly different
(44.1% vs. 48.6%; p = 0.538), and long-term survival results
were similar.
Figure 1 Kaplan Meier curves of (a) Local control rate, (b) relapse-free survival, and (c) overall survival. Solid line=capecitabine alone.
Dashed line=capecitabine/irinotecan.
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This study assessed whether combining irinotecan with
capecitabine was more effective in patients with locally
advanced rectal cancer than capecitabine alone. Basedon the radiologic and pathologic findings, we attempted
to compare the short-term tumor responses of the two
treatment groups. As mentioned above, we found no
meaningful differences between the two groups. We also
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groups by assessing the 5-year local control rate, relapse-
free survival, and overall survival. Similar to the results
of short-term tumor response, combining irinotecan with
capecitabine did not provide any meaningful benefit in
survival over capecitabine alone. Thus, the addition of
irinotecan to a capecitabine regimen does not have sig-
nificant advantages over capecitabine alone and is not
recommended as a treatment of choice in the clinic.
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